Skip Navigation

Annals of Oncology 2007 18(12):1919; doi:10.1093/annonc/mdm524
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

in this issue

In this issue

The first 10% of the full text of this article appears below.


   BiotHER and response to trastuzumab
 
Besides the accurate assessment of HER2 status, additional predictive parameters are needed to identify more precisely those breast cancer patients most likely to benefit from trastuzumab therapy. Neither FISH nor the most widely used immunohistochemical methods to detect HER2 overexpression actually document the presence of the specific target site of trastuzumab, which is located in the juxtamembrane region of the extracellular domain. Sapino et al. hypothesized that using trastuzumab as the primary antibody to reveal the presence . . . [Full Text of this Article]


   PAI-1 in colorectal cancer prognosis
 

   Pamidronate-related jaw necrosis in multiple myeloma patients
 

   Cancer treatment and muscular fitness
 

   Quote
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?